MaaT Pharma Patient Dosing Phase 2b Trial for Blood Cancer

MaaT Pharma, a clinical-stage biotech firm, has recently disclosed the commencement of its phase 2b trial, named PHOEBUS. This trial aims to evaluate the effectiveness of MaaT033 in enhancing the overall survival (OS) of blood cancer patients, undergoing allo-HSCT treatment. The company is delighted to report that the first patient has now been treated under this trial. The trial, labeled as NCT05762211, is anticipated to take place in multiple centers across the globe. It will be an international study, following a randomized, double-blind, placebo-control design.

Up to 56 clinical investigation sites will be involved in this research, with a target enrolment of 387 patients. To this day, it stands as the most extensive randomized controlled trial evaluating a microbiome therapy in the field of oncology. Today is a momentous occasion for us because our second product, MaaT033, has now commenced phase 2b clinical trials in allo-HSCT. According to Hervé Affagard, the CEO and co-founder of MaaT Pharma, providing patients with a capsule that can be consumed at home not only aligns with our mission to enhance patient survival in various scenarios, but also strengthens our position as leaders in the microbiome/haemato-oncology domain. Affagard further asserts that our programme is presently the most advanced in this field. Dear Professor, I hope this message finds you well. I wanted to discuss an important matter with you regarding the upcoming project. Florent Malard, a Haematology Professor at the Saint-Antoine Hospital and Sorbonne University, and also the principal investigator of the study, made an additional statement. He expressed that there is an increasing amount of evidence suggesting that an imbalance in the gut is associated with elevated mortality rates within our field.